Literature DB >> 10440999

Molecular genetic basis of pancreatic adenocarcinoma.

W Hilgers1, S E Kern.   

Abstract

Pancreatic ductal adenocarcinoma is a complex genetic disease. As might be expected for a malignancy that is rather homogeneous in clinical presentation and behavior, a distinct subset of genes are found to be genetically inactivated in a majority of the tumors. A yet larger subset of genes experiences genetic inactivation at much lower frequencies. The latter subset could solely reflect a somewhat trivial genetic heterogeneity of the tumor, but more likely will represent the initial insights into pathways whose more widespread importance will be shown in future work. Familial pancreatic cancer susceptibility underlies a significant fraction of the overall incidence. Genetic testing is feasible for many of the causative genes, although the clinical utility remains unsettled. The precursor lesion for pancreatic cancer shares some of the genetic lesions of the more advanced invasive stage, and follows a stepwise progression model both histologically and genetically. Genes Chromosomes Cancer 26:1-12, 1999. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  1999        PMID: 10440999

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

1.  Imaging cancer gene activity in patients from outside the body.

Authors:  Eric Wickstrom; Mathew L Thakur
Journal:  Biotechnol Healthc       Date:  2006-02

Review 2.  Pancreatic biomarkers: could they be the answer?

Authors:  Angela Lamarca; Jaime Feliu
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

3.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells.

Authors:  Z Su ; I V Lebedeva; R V Gopalkrishnan; N I Goldstein; C A Stein; J C Reed; P Dent; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

4.  Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.

Authors:  Seema Gupta; Sabapathi Sathishkumar; Mansoor M Ahmed
Journal:  Pancreatology       Date:  2010-10-29       Impact factor: 3.996

5.  Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma.

Authors:  Maria A Kouvaraki; Anita L Korapati; George Z Rassidakis; Ling Tian; Qingxiu Zhang; Paul Chiao; Linus Ho; Douglas B Evans; François X Claret
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Muir-Torre-like syndrome in Fhit-deficient mice.

Authors:  L Y Fong; V Fidanza; N Zanesi; L F Lock; L D Siracusa; R Mancini; Z Siprashvili; M Ottey; S E Martin; T Druck; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 7.  Mouse models of pancreatic cancer.

Authors:  Marta Herreros-Villanueva; Elizabeth Hijona; Angel Cosme; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

8.  Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Authors:  Steven L Warner; Ruben M Muñoz; David J Bearss; Paul Grippo; Haiyong Han; Daniel D Von Hoff
Journal:  Pancreas       Date:  2008-10       Impact factor: 3.327

9.  The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells.

Authors:  Valérie Fauquette; Michael Perrais; Sylvain Cerulis; Nicolas Jonckheere; Marie-Paule Ducourouble; Jean-Pierre Aubert; Pascal Pigny; Isabelle Van Seuningen
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

10.  Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

Authors:  P Tassone; P Tagliaferri; C Viscomi; C Palmieri; M Caraglia; A D'Alessandro; E Galea; A Goel; A Abbruzzese; C R Boland; S Venuta
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.